| SEC Form 4 | |
|------------|--|
|------------|--|

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number: | 3235-0287 | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

| STATEMENT | OF CHANGES | IN BENEFICIAL | OWNERSHIP |
|-----------|------------|---------------|-----------|
| | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | or Section So(ii) of the investment company Act of 1940 | | | | | | |
|---|-------------|----------|---|--|--|--|--|--|--|
| 1. Name and Address of Reporting Person [*] Mulligan Seamus | | Person* | 2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
| | | | i ii | X Director 10% Owner | | | | | |
| - | | | я <u></u> | Officer (give title Other (specify | | | | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 05/26/2020 | below) below) | | | | | |
| 5TH FL, WAT | TERLOO EXCH | IANGE | 00/20/2020 | | | | | | |
| WATERLOO | RD | | | | | | | | |
| | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) | | | | X Form filed by One Reporting Person | | | | | |
| DUBLIN 4 | L2 | | _ | Form filed by More than One Reporting Person | | | | | |
| (City) | (State) | (Zip) | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transa Code (8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|---------------------------------|--|---|------------------------------|---|--|---------------|-----------------------------------|--|--|---|--|
| | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | | |
| Ordinary Shares | 05/26/2020 | | Р | | 15,000 | A | \$ 110.6498 ⁽¹⁾ | 1,117,788 | D | | |
| Ordinary Shares | 05/27/2020 | | Р | | 5,243 | A | \$109.5516 ⁽²⁾ | 1,123,031 | D | | |
| Ordinary Shares | 05/27/2020 | | Р | | 8,391 | A | \$110.5174 ⁽³⁾ | 1,131,422 | D | | |
| Ordinary Shares | 05/27/2020 | | Р | | 9,884 | A | \$111.5623 ⁽⁴⁾ | 1,141,306 | D | | |
| Ordinary Shares | 05/27/2020 | | Р | | 11,482 | A | \$ 112.3189 ⁽⁵⁾ | 1,152,788 | D | | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | | | of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 | | Expiration Date (Month/Day/Year) vurities uprities or posed D) tr 3, 4 | | Expiration Date | | Amount of | | Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|-----|-----|--|--------------------|---|--|-----------------|--|-----------|--|--------------------------------------|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | | | |

Explanation of Responses:

1. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from \$110.1800 to \$110.9800. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.


2. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from \$109.0300 to \$110.0200. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares

and prices at which the purchases were effected.

3. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from 110.0300 to \$111.0100. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

4. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from \$111.0350 to \$112.0200. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

5. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from \$112.0500 to \$112.6600. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.



** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.